Related Experiment Video
Updated: Jun 4, 2026

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
Published on: June 2, 2022
[Paroxysmal nocturnal hemoglobinuria therapy with eculizumab: Spanish experience]
Montserrat López Rubio1, Marta Morado, Ana Gaya
1Servicio de Hematología y Hemoterapia, Hospital Universitario Príncipe de Asturias, Madrid, España. montserratlr@terra.es
Background And Objectives:
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal disease characterized by complement-mediated hemolysis, bone marrow failure and thrombosis. Eculizumab is a humanized monoclonal antibody that blocks the cytolytic component of the complement system by binding to complement C5.
Material And Methods:
We report the results of eculizumab treatment in 25 PNH patients from different centers in Spain. Statistical analysis was perfomed with a SPSS v15.0 software.
Results:
Fifty-eight per cent of the patients achieved transfusional independence after a median of 14 months. Transfusion requirements were reduced in 60% of the remaining cases. Fatigue resolved in 96% of the patients and smooth muscle dystony-related symptoms in all cases. A single case of treatment-related infection was observed.
Conclusions:
Eculizumab controls effectively hemolysis and greatly improves clinical symptoms. The drug is safe and well tolerated, without significant adverse effects except meningococcal infection. Patients with suboptimal response to treatment must be assessed for bone marrow insufficiency and extravascular haemolysis.
Related Concept Videos
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents